Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) (S.A.E) (EGX:RMDA)

Market Cap	8.14B +30.1%
Revenue (ttm)	4.10B +47.9%
Net Income	298.46M -23.0%
EPS	0.13 -26.2%
Shares Out	2.00B
PE Ratio	30.46
Forward PE	13.83
Dividend	0.04 (0.99%)
Ex-Dividend Date	n/a

Volume	13,466,990
Average Volume	26,007,115
Open	4.100
Previous Close	4.100
Day's Range	4.040 - 4.120
52-Week Range	3.022 - 5.120
Beta	0.36
RSI	43.25
Earnings Date	May 14, 2026

About EGX:RMDA

Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) (S.A.E), together with its subsidiaries, produces and sells a range of branded generic pharmaceuticals, food supplements, veterinary products, and nutraceuticals in Egypt. The company manufactures, markets, sells, and stores pharmaceutical reagents for human and veterinary use, and diagnostic reagents for individuals, laboratories, and hospitals; imports pharmaceutical reagents and raw materials; and produces food supplements for human use. It offers a portfolio of ...

• Industry: Pharmaceutical Preparations
• Founded: 1986
• Country: Egypt
• Stock Exchange: Egyptian Stock Exchange
• Ticker Symbol: RMDA

Financial Performance

In 2025, EGX:RMDA's revenue was 4.10 billion, an increase of 47.94% compared to the previous year's 2.77 billion. Earnings were 298.46 million, a decrease of -17.97%.